Acelyrin (SLRN) to Release Earnings on Thursday

Acelyrin (NASDAQ:SLRN) is projected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

Acelyrin (NASDAQ:SLRN) last issued its earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.07. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acelyrin Stock Performance

Acelyrin stock opened at $2.64 on Tuesday. The company has a market capitalization of $265.87 million, a PE ratio of -1.07 and a beta of 1.27. The company has a 50 day moving average price of $2.30 and a 200-day moving average price of $3.79. Acelyrin has a fifty-two week low of $1.85 and a fifty-two week high of $7.30.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SLRN. Citigroup lowered their price objective on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Wells Fargo & Company cut their price objective on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Finally, HC Wainwright dropped their target price on Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $9.60.

Insiders Place Their Bets

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the sale, the chief executive officer now owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 13.60% of the company’s stock.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.